Biogen Prepares More Doubtful Phase III Results For FDA Scrutiny, This Time In ALS
Will Hope To Ride On Coattails Of Amylyx’s Thumbs Up
Even if approved, tofirsen looks unlikely to be a big earner for Biogen, which is depending on other late-stage candidates to revive its fortunes. 
